Actively Recruiting
Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach
Led by Peking University Cancer Hospital & Institute · Updated on 2025-09-16
30
Participants Needed
1
Research Sites
240 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if treatment modality including Disitamab Vedotin （RC48）, Oxaliplatin，Tegafur,Gimeracil and Oteracil Porassium Capsules （SOX）and Sindillimab works to treat locally advanced hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are: * To evaluate the perioperative efficacy of RC48 combined with sindillizumab and SOX in the treatment of locally advanced HER2-expressing hepatoid adenocarcinoma of stomach * To evaluate the safety and long-term benefits of RC48 combined with sindillizumab and SOX regimens in perioperative treatment of locally advanced HER2-expressing hepatoid adenocarcinoma of stomach Participants will: * Preoperative treatment with RC48, SOX and sindillizumab for 4 cycles * Radical surgery after 4-6 weeks of the preoperative treatment * Adjuvant treatment with RC48, Tegafur,Gimeracil and Oteracil Porassium Capsules and sindillizumab for 4 cycles
CONDITIONS
Official Title
Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed gastric hepatoid adenocarcinoma by pathological biopsy
- HER2 expression with Immunohistochemistry scores of 1+, 2+, or 3+
- Clinical stage II or III disease
- Expected to complete R0 surgical excision
- ECOG performance status of 0 to 1
- Generally in good condition and able to tolerate perioperative treatment and surgery
- Voluntary enrollment in the study
You will not qualify if you...
- Presence of other malignant tumors except thyroid papillary carcinoma, facial basal cell carcinoma, or other low-grade malignant tumors
- Need for surgical intervention due to obstruction, bleeding, or similar conditions as evaluated by clinicians
- dMMR/MSIH status
- Prior anti-tumor therapy before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital & Institute
Beijing, China
Actively Recruiting
Research Team
A
Anqiang Wang
CONTACT
J
Jialin Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here